Solution for injection in a pre-filled syringe. Each pre-filled syringe (5 ml) contains 250 mg fulvestrant. Clear, colorless to yellow, viscous solution free of particles.
Fulvestrant EVER Pharma is intended for:
as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- who have not previously received endocrine therapy or
- with recurrence during or after adjuvant anti-estrogen therapy or disease progression with anti-estrogen therapy.
in combination with palbociclib for the treatment of hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced or metastatic breast cancer in women who have previously received endocrine therapy (see Fass section 5.1).
Fulvestrant is a competitive estrogen receptor antagonist (ER) with an affinity comparable to estradiol. Fulvestrant blocks the trophic effects of estrogens without any partial agonist (estrogen-like) activity.
The mechanism of action is associated with down-regulation of estrogen receptor protein levels.
Clinical studies performed in postmenopausal women with primary breast cancer have shown that fulvestrant significantly downregulates estrogen receptor protein in estrogen receptor positive tumors compared to placebo
No special storage instructions, no need to store in the refrigerator.
Available in pre-filled syringe 10 x 5 ml disposable syringes
10 x 5 ml: 403760
For more information:
Note that the appearance of the packaging may differ depending on the country.
The page was last updated on 2021-04-01